Preparation process of litexitinib tosylate
Through a simplified three-step reaction route, the preparation efficiency and economicality of litxitinib toluenesulfonate are successfully improved by using the amidation reaction of carbonyl and amino groups and the separation of L-DBTA, combining p-methylsulfonic acid tosylate. Solve the problems of complex and inefficient existing processes.
Patent Information
- Application Number
- CN202411152271.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The existing preparation process of litxitinib toluenesulfonate is complex and inefficient, and lacks an efficient synthetic route.
The amidation reaction of carbonyl and amino groups was adopted, and after L-DBTA resolution, it finally reacted with p-methylsulfonic acid, which was simplified into a 3-step reaction route, which improved the preparation efficiency and yield.
It realizes a simplified synthesis route, reduces the experimental cycle, avoids the use of expensive reagents, improves the purity and economy of the product, and is suitable for industrial production.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to a preparation process of rituximab tosylate. Background Art
[0002] Ritlecitinib Tosylate is a novel oral targeted Janus kinase 3 (JAK3) inhibitor that can effectively block the activity of signaling molecules and immune cells, which are believed to be the cause of alopecia areata. On June 23, 2023, Pfizer announced that the U.S. FDA approved the marketing of the innovative drug Ritlecitinib Tosylate Capsules (trade name: LITFULO) for the treatment of severe alopecia areata in people aged 12 years and above. In the field of alopecia areata treatment, this is the second targeted immunosuppressant approved by the FDA and the only treatment for adolescents with severe alopecia areata.
[0003] The chemical name of rituximab tosylate is: 1-{(2S,5R)-2-methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid, and the chemical structure is shown in Formula I:
[0004]
[0005] However, the current preparation process of rituximab tosylate still needs to be improved. Summary of the invention
[0006] The present invention aims to solve at least one of the technical problems in the related art to a certain extent. To this end, one object of the present invention is to provide a preparation process of the compound rituximab tosylate shown in formula I. Compared with the prior art, the steps of this route are shortened to 3 steps. The raw materials of the method of the present invention are subjected to amidation reaction of carbonyl and amino groups, and the amide is reduced and then separated by L-DBTA to obtain the desired chiral compound, and finally salified with p-toluenesulfonic acid to obtain the target compound.
[0007] In one aspect of the present invention, the present invention provides a preparation process of rituximab tosylate, a compound represented by formula I. According to an embodiment of the present invention, the preparation process comprises:
[0008] (1) contacting the compound represented by Formula 1 with the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 to obtain the compound represented by Formula 3;
[0009] (2) contacting the compound represented by Formula 3 with L-DBTA to obtain the compound represented by Formula 4;
[0010] (3) contacting the compound represented by formula 4 with p-toluenesulfonic acid to obtain the compound represented by formula I, rituximab tosylate,
[0011]
[0012] The inventors have found that, by utilizing the preparation process of the present invention, using the compound represented by Formula 1 and the compound represented by Formula 2 as starting materials, a total of three steps of reaction can be performed to successfully synthesize and prepare the target product, rituximab tosylate.
[0013] The term "contact" as used herein should be understood in a broad sense, and can be any manner that allows at least two reactants to undergo a chemical reaction, such as mixing the two reactants under appropriate conditions. If necessary, the reactants to be contacted can be mixed under stirring, and thus, the type of stirring is not particularly limited, and can be mechanical stirring, i.e. stirring under the action of mechanical force.
[0014] In this document, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.
[0015] According to an embodiment of the present invention, the method for preparing the compound represented by Formula 3, the compound represented by Formula 4, and the compound represented by Formula I may also have at least one of the following additional technical features:
[0016] According to an embodiment of the present invention, the chemical reaction described in the present invention can be carried out according to any method known in the art. The source of the raw materials of the compound shown in Formula 3, the compound shown in Formula 4, and the compound shown in Formula I is not particularly limited, and they can be prepared by any known method or obtained commercially.
[0017] According to an embodiment of the present invention, in step (1), the contacting method of the compound represented by Formula 1 with the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 is not particularly limited. Thus, the efficiency of the contact reaction between the compound represented by Formula 1 and the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound represented by Formula 3 by using this method can be further improved.
[0018] According to an embodiment of the present invention, in step (1), the following steps are included: maintaining the temperature at 5°C to 12°C, adding the compound of formula 1, the compound of formula 2, and glacial acetic acid to 1,2-dichloroethane, maintaining the temperature at 8°C to 10°C and stirring for 10 hours, then adding sodium triacetoxyborohydride (NaBH(OAc)3) to the reaction solution and heating to 32°C to 40°C for reaction for 4 hours, then cooling the reaction solution to room temperature, adding saturated ammonium chloride solution to quench, then adding 1M NaOH aqueous solution for washing, adding ethyl acetate for extraction twice, combining the organic phases, adding saturated brine for washing, drying over anhydrous sodium sulfate, concentrating the organic phase under reduced pressure, and purifying the concentrate by silica gel column chromatography with a petroleum ether / ethyl acetate mixed solvent to obtain the compound of formula 3. Thus, the efficiency of the contact reaction between the compound of formula 1 and the compound of formula 2, glacial acetic acid, and NaBH(OAc)3 can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound of formula 3 by using this method can be further improved.
[0019] According to an embodiment of the present invention, in step (1), the molar ratio of the compound represented by Formula 1 to the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 is 1:(1.0-1.15):1.0:(1.3-1.6), and preferably the molar ratio of the compound represented by Formula 1 to the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 is 1:1.05:1.0:1.4. Thus, the efficiency of preparing the compound represented by Formula 3 by this method can be further improved.
[0020] According to an embodiment of the present invention, in step (1), the temperature is preferably raised to 36° C. and reacted for 4 hours.
[0021] According to an embodiment of the present invention, in step (1), the volume ratio of the petroleum ether / ethyl acetate mixed solvent is 1:(6-10), preferably the volume ratio of the petroleum ether / ethyl acetate mixed solvent is 1:8.
[0022] According to a specific embodiment of the present invention, in step (1), the following steps are included: maintaining the temperature at 5°C to 12°C, adding the compound represented by formula 1 (16.72 g, 0.10 mol), the compound represented by formula 2 (14.08 g, 0.105 mol), and glacial acetic acid (6.0 g, 0.10 mol) to 1,2-dichloroethane (200 mL), maintaining the temperature at 8°C to 10°C and stirring for 10 hours, then adding NaBH(OAc)3 (29.67 g, 0.14 mol) to the reaction solution and heating The mixture was heated to 36°C for 4 hours, then cooled to room temperature, quenched by adding saturated ammonium chloride solution (20 mL), washed with 1 M NaOH aqueous solution (150 mL), extracted twice with ethyl acetate (150 mL each time), combined with the organic phases, washed with 150 mL saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography with a petroleum ether / ethyl acetate mixed solvent in a volume ratio of 1:8 to obtain the compound of formula 3, with an amount of 21.80 g and a yield of 76.4%.
[0023] According to an embodiment of the present invention, in step (2), the contacting method of the compound represented by Formula 3 and L-DBTA is not particularly limited. Thus, the efficiency of the contact reaction between the compound represented by Formula 3 and L-DBTA can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound represented by Formula 4 by using this method can be further improved.
[0024] According to an embodiment of the present invention, in step (2), the following steps are included: adding methanol to a reaction bottle containing the compound of formula 3 and (-)-dibenzoyl-L-tartaric acid (L-DBTA) at room temperature, stirring and dissolving, heating to reflux, stirring and reacting for 10 to 12 hours, observing that a large amount of solid is precipitated in the solution, cooling the reaction solution to room temperature, crystallizing and stirring for 2 hours, and then filtering, adding methanol to the filter cake for elution, adding dichloromethane and 5% Na2CO3 solution, stirring and dissolving, separating the liquids, adding saturated salt water to the organic phase for washing, drying with anhydrous sodium sulfate, and concentrating under reduced pressure to obtain a solid, which is the compound of formula 4. Thus, the efficiency of the contact reaction between the compound of formula 3 and L-DBTA can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound of formula 4 by using this method can be further improved.
[0025] According to an embodiment of the present invention, in step (2), the molar ratio of the compound represented by formula 3 to L-DBTA is 1:(0.6-0.7), preferably the molar ratio of the compound represented by formula 3 to L-DBTA is 1:0.65. Thus, the efficiency of preparing the compound represented by formula 4 by this method can be further improved.
[0026] According to an embodiment of the present invention, in step (2), the time for heating to reflux state and stirring the reaction is preferably 11 hours.
[0027] According to a specific embodiment of the present invention, in step (2), the following steps are included: at room temperature, 200 mL of methanol is added to a reaction bottle containing the compound of formula 3 (18.90 g, 66.24 mmol) and (-)-dibenzoyl-L-tartaric acid (L-DBTA) (15.43 g, 43.06 mmol), and the mixture is stirred and dissolved. The mixture is heated to reflux and stirred for 11 hours. A large amount of solid is observed to precipitate from the solution. The reaction solution is cooled to room temperature, crystallized and stirred for 2 hours, and then filtered. 20 mL of methanol is added to the filter cake for elution. 150 mL of dichloromethane and 150 mL of 5% Na2CO3 solution are added, the mixture is stirred and dissolved, and the mixture is separated. 150 mL of saturated brine is added to the organic phase for washing, the organic phase is dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a solid, i.e., the compound of formula 4, with an amount of 8.30 g, a purity of 98.4%, ee>98.5%, and a yield of 43.9%.
[0028] According to an embodiment of the present invention, in step (3), the contacting method of the compound represented by Formula 4 with p-toluenesulfonic acid is not particularly limited. Thus, the efficiency of the contacting reaction of the compound represented by Formula 4 with p-toluenesulfonic acid can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound represented by Formula I by using this method can be further improved.
[0029] According to an embodiment of the present invention, in step (3), the following steps are included: at room temperature, dissolving the compound shown in Formula 4 in an organic solvent C, slowly dropping p-toluenesulfonic acid, maintaining stirring at room temperature for 1 hour, precipitating a large amount of solids, filtering the solids, washing the filter cake with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallizing with methanol, and vacuum drying the filtered filter cake to obtain the compound shown in Formula I, rituximab tosylate. Thus, the efficiency of the contact reaction between the compound shown in Formula 4 and p-toluenesulfonic acid can be improved, the reaction speed can be accelerated, and the efficiency of preparing the compound shown in Formula I, rituximab tosylate, by using this method can be further improved.
[0030] According to an embodiment of the present invention, in step (3), the molar ratio of the compound represented by formula 4 to p-toluenesulfonic acid is 1:(1.05-1.2), preferably the molar ratio of the compound represented by formula 4 to p-toluenesulfonic acid is 1:1.1. Thus, the efficiency of preparing the compound represented by formula I by this method can be further improved.
[0031] According to an embodiment of the present invention, in step (3), the organic solvent C is at least one selected from ethanol, acetone, or tetrahydrofuran.
[0032] According to a specific embodiment of the present invention, in step (3), the following steps are included: at room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) is dissolved in 30 mL of ethanol, p-toluenesulfonic acid (1.93 g, 11.20 mmol) is slowly added dropwise, and the mixture is stirred at room temperature for 1 hour to precipitate a large amount of solid, the solid is filtered, the filter cake is washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake is vacuum dried to obtain the compound represented by formula I, i.e., 3.96 g, with a yield of 85.2% and a HPLC purity of 99.8%.
[0033] According to a specific embodiment of the present invention, the synthetic route of the compound of formula I, rituximab tosylate, can be as follows:
[0034]
[0035] Compared with the prior art, the preparation process of rituximab tosylate described in the present invention has at least the following beneficial effects:
[0036] 1. The raw materials of the method of the present invention are subjected to an amidation reaction between the carbonyl group and the amino group, and the amide is reduced and then split by L-DBTA to obtain the desired chiral compound, and finally salified with p-toluenesulfonic acid to obtain the target compound, rituximab tosylate.
[0037] 2. Compared with the prior art methods, the present invention has the following significant advantages: (1) The chemical substances used in this synthesis route are all commercially available products. When the reaction is carried out, the operation method and operation steps, reaction conditions and intermediates adopted are all of good operability. In addition, the reaction route steps of the design method are short, the experimental cycle is short, and it is easy to scale up the synthesis. (2) The synthesis is carried out using a raw material of an available chiral isomer, which avoids the two chiral chromatographic column separations in the prior art method and has better economy; (3) In the prior art, (R)-N-3,5-dinitrobenzoylphenylglycine is used as a separation agent, which is expensive. The separation agent (L-DBTA) used in the preparation method is low in price, the reagent is easy to obtain, and expensive reagents are avoided; the reaction is mild, the operation is safe, and the separation safety is high; column chromatography purification is avoided, which is conducive to industrial production. (4) The raw materials selected by the present invention are easy to obtain, the operation method is simple, and the product yield is high. DETAILED DESCRIPTION
[0038] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.
[0039] Example 1 Synthesis of the compound represented by formula 3
[0040] The compound represented by Formula 1 (16.72 g, 0.10 mol), the compound represented by Formula 2 (14.08 g, 0.105 mol), and glacial acetic acid (6.0 g, 0.10 mol) were added to 1,2-dichloroethane (200 mL) at 5°C to 12°C, and the temperature was maintained at 8°C to 10°C and stirred for 10 hours. Then, sodium triacetoxyborohydride (NaBH(OAc)3) (29.67 g, 0.14 mol) was added to the reaction solution and the temperature was raised to 36°C for 4 hours. The reaction solution was cooled to room temperature, saturated ammonium chloride solution (20 mL) was added to quench, and then 1 M NaOH aqueous solution (150 ml) was added to wash, and ethyl acetate was added to extract twice (150 ml each time), and the organic phases were combined and washed with 150 ml of saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography using a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 1:8 to obtain the compound shown in Formula 3, with an amount of 21.80 g and a yield of 76.4%.
[0041] LC-MS (APCI): m / z = 286.2 (M+1) + .
[0042] Example 2 Synthesis of the compound represented by formula 3
[0043] The compound represented by Formula 1 (16.72 g, 0.10 mol), the compound represented by Formula 2 (13.41 g, 0.10 mol), and glacial acetic acid (6.0 g, 0.10 mol) were added to 1,2-dichloroethane (200 mL) at 5°C to 12°C, and the temperature was maintained at 8°C to 10°C and stirred for 10 hours. Then, NaBH(OAc)3 (27.55 g, 0.13 mol) was added to the reaction solution and the temperature was raised to 32°C for 4 hours. Then, the reaction mixture was stirred for 10 hours. The reaction mixture was cooled to room temperature, quenched by adding saturated ammonium chloride solution (20 mL), then washed with 1 M NaOH aqueous solution (150 ml), extracted twice with ethyl acetate (150 ml each time), combined the organic phases, washed with 150 ml saturated brine, dried over anhydrous sodium sulfate, concentrated the organic phase under reduced pressure, and purified the concentrate by silica gel column chromatography with a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 1:6 to obtain the compound of formula 3, with an amount of 21.23 g and a yield of 74.4%.
[0044] Example 3 Synthesis of the compound represented by formula 3
[0045] The compound represented by Formula 1 (16.72 g, 0.10 mol), the compound represented by Formula 2 (15.43 g, 0.115 mol), and glacial acetic acid (6.0 g, 0.10 mol) were added to 1,2-dichloroethane (200 mL) at 5°C to 12°C, and the temperature was maintained at 8°C to 10°C and stirred for 10 hours. Then, NaBH(OAc)3 (33.91 g, 0.16 mol) was added to the reaction solution and the temperature was raised to 40°C for 4 hours. Then, the reaction mixture was stirred for 10 hours. The reaction mixture was cooled to room temperature, quenched by adding saturated ammonium chloride solution (20 mL), then washed with 1 M NaOH aqueous solution (150 ml), extracted twice with ethyl acetate (150 ml each time), combined the organic phases, washed with 150 ml saturated brine, dried over anhydrous sodium sulfate, concentrated the organic phase under reduced pressure, and purified the concentrate by silica gel column chromatography with a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 1:10 to obtain the compound of formula 3, with an amount of 21.63 g and a yield of 75.8%.
[0046] Comparative Example 1: Synthesis of the compound represented by Formula 3
[0047] The molar ratio of the compound represented by Formula 1 to the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 was adjusted to 1:0.98:1.2:1.1, the temperature was maintained at 8°C to 10°C, and the stirring time was adjusted to 9 hours.
[0048] The compound represented by Formula 1 (16.72 g, 0.10 mol), the compound represented by Formula 2 (13.14 g, 0.098 mol), and glacial acetic acid (7.2 g, 0.12 mol) were added to 1,2-dichloroethane (200 mL) at 5°C to 12°C, and the temperature was maintained at 8°C to 10°C and stirred for 9 hours. Then, NaBH(OAc)3 (23.31 g, 0.11 mol) was added to the reaction solution and the temperature was raised to 36°C for 4 hours. Then, the reaction mixture was stirred for 2 hours. The reaction mixture was cooled to room temperature, quenched by adding saturated ammonium chloride solution (20 mL), then washed with 1 M NaOH aqueous solution (150 ml), extracted twice with ethyl acetate (150 ml each time), combined the organic phases, washed with 150 ml saturated brine, dried over anhydrous sodium sulfate, concentrated the organic phase under reduced pressure, and purified the concentrate by silica gel column chromatography with a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 1:8 to obtain the compound of formula 3, with an amount of 21.55 g and a yield of 72.0%.
[0049] Comparative Example 2: Synthesis of the compound represented by Formula 3
[0050] The molar ratio of the compound represented by Formula 1 to the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 was adjusted to 1:1.3:1.0:1.8.
[0051] The compound represented by Formula 1 (16.72 g, 0.10 mol), the compound represented by Formula 2 (17.44 g, 0.13 mol), and glacial acetic acid (6.0 g, 0.10 mol) were added to 1,2-dichloroethane (200 mL) at 5°C to 12°C, and the temperature was maintained at 8°C to 10°C and stirred for 10 hours. Then, NaBH(OAc)3 (38.15 g, 0.18 mol) was added to the reaction solution and the temperature was raised to 40°C for 4 hours. Then, the reaction mixture was stirred for 10 hours. The reaction mixture was cooled to room temperature, quenched by adding saturated ammonium chloride solution (20 mL), then washed with 1 M NaOH aqueous solution (150 ml), extracted twice with ethyl acetate (150 ml each time), combined the organic phases, washed with 150 ml saturated brine, dried over anhydrous sodium sulfate, concentrated the organic phase under reduced pressure, and purified the concentrate by silica gel column chromatography with a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 1:8 to obtain the compound of formula 3, with an amount of 21.11 g and a yield of 74.0%.
[0052] Example 4 Synthesis of the compound represented by formula 4
[0053] At room temperature, 200 mL of methanol was added to a reaction bottle containing the compound of formula 3 (18.90 g, 66.24 mmol) and (-)-dibenzoyl-L-tartaric acid (L-DBTA) (15.43 g, 43.06 mmol), and the mixture was stirred and dissolved. The mixture was heated to reflux and stirred for 11 hours. A large amount of solid was observed to precipitate from the solution. The reaction solution was cooled to room temperature, crystallized and stirred for 2 hours, and then filtered. 20 mL of methanol was added to the filter cake for elution. 150 mL of dichloromethane and 150 mL of 5% Na2CO3 solution were added, and the mixture was stirred and dissolved. The organic phase was washed with 150 mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a solid, i.e., the compound of formula 4, with an amount of 8.30 g, a purity of 98.4%, ee>98.5%, and a yield of 43.9%.
[0054] LC-MS (APCI): m / z = 286.2 (M+1) + .
[0055] IH-NMR (400MHz, DMSO-d6): δppm 11.52(s,1H),8.11(d,1H),7.44-7.20(m,1H),7.09(s,1H),6.81(dd,J=30.9,17.3Hz,1H),6.54(dd,1H),6.09(dd,J=16.7,2.0Hz,1H),5.66(dd J=10.5,1.9Hz,1H),4.81(s,0.5H),4.55(d,J=13.2Hz,0.5H),4.36(s,0.5H),4.11- 4.04(m,1.5H),2.96(t,0.5H),2.58(t,0.5H),1.94-1.54(m,4H),1.16-1.26(m,3H).
[0056] Example 5 Synthesis of the compound represented by formula 4
[0057] At room temperature, 200 mL of methanol was added to a reaction bottle containing the compound of formula 3 (18.90 g, 66.24 mmol) and L-DBTA (14.24 g, 39.74 mmol), and the mixture was stirred and dissolved. The mixture was heated to reflux and stirred for 10 hours. A large amount of solid was observed to precipitate in the solution. The reaction solution was cooled to room temperature, crystallized and stirred for 2 hours, and then filtered. 20 mL of methanol was added to the filter cake for elution. 150 mL of dichloromethane and 150 mL of 5% Na2CO3 solution were added, and the mixture was stirred and dissolved. The mixture was separated. 150 mL of saturated brine was added to the organic phase for washing, and the mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a solid, which was the compound of formula 4. The yield was 7.77 g, the purity was 98.1%, ee>98.5%, and the yield was 41.1%.
[0058] Example 6 Synthesis of the compound represented by formula 4
[0059] At room temperature, 200 mL of methanol was added to a reaction bottle containing the compound of formula 3 (18.90 g, 66.24 mmol) and L-DBTA (16.61 g, 46.37 mmol), and the mixture was stirred and dissolved. The mixture was heated to reflux and stirred for 12 hours. A large amount of solid was observed to precipitate from the solution. The reaction solution was cooled to room temperature, stirred for 2 hours, and then filtered. 20 mL of methanol was added to the filter cake for elution. 150 mL of dichloromethane and 150 mL of 5% Na2CO3 solution were added, and the mixture was stirred and dissolved. The mixture was separated. 150 mL of saturated brine was added to the organic phase for washing, and the mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a solid, which was the compound of formula 4. The yield was 8.18 g, the purity was 98.3%, ee>98.5%, and the yield was 43.3%.
[0060] Example 7 Synthesis of the compound represented by formula I
[0061] At room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) was dissolved in 30 mL of ethanol, and p-toluenesulfonic acid (1.93 g, 11.20 mmol) was slowly added dropwise, and the mixture was stirred at room temperature for 1 hour. A large amount of solid was precipitated, and the solid was filtered. The filter cake was washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake was vacuum dried to obtain the compound represented by formula I, rituximab tosylate, with an amount of 3.96 g, a yield of 85.2%, and an HPLC purity of 99.8%.
[0062] LC-MS (APCI): m / z=286.2(M+1)+.
[0063] 1 H NMR (400MHz, DMSO-d6): δppm 12.69(brs,1H),9.24(brs,1H),8.42(s,1H),7.52(d,J=8.1Hz,2H),7.47(m,1H) ,7.14(d,J=8.3Hz,2H),6.95(d,J=1.2Hz,1H),6.88(m,1H),6.15(m,1H),5.75(m, 1H),4.82(m,0.5H),4.58(m,0.5H),4.43(m,0.5H),4.13(m,0.5H),3.98(m,1H),3 .14(m,0.5H),2.84(m,0.5H),2.28(s,3H),1.90-1.75(m,4H),1.28-1.19(m,3H).
[0064] Example 8 Synthesis of the compound represented by formula I
[0065] At room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) was dissolved in 30 mL of ethanol, and p-toluenesulfonic acid (1.84 g, 10.67 mmol) was slowly added dropwise, and the mixture was stirred at 20-25 ° C for 1 hour. A large amount of solid was precipitated, and the solid was filtered. The filter cake was washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake was vacuum dried to obtain the compound represented by formula I, rituximab tosylate, with an amount of 3.81 g, a yield of 81.9%, and an HPLC purity of 99.6%.
[0066] Example 9 Synthesis of the compound represented by formula I
[0067] At room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) was dissolved in 30 mL of ethanol, and p-toluenesulfonic acid (2.10 g, 12.19 mmol) was slowly added dropwise, and the mixture was stirred at 20-25 ° C for 1 hour. A large amount of solid was precipitated, and the solid was filtered. The filter cake was washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake was vacuum dried to obtain the compound represented by formula I, ibutinib tosylate, with an amount of 3.92 g, a yield of 84.3%, and a HPLC purity of 99.5%.
[0068] Example 10 Synthesis of the compound represented by formula I
[0069] At room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) was dissolved in 30 mL of acetone, and p-toluenesulfonic acid (1.93 g, 11.20 mmol) was slowly added dropwise, and the mixture was stirred at 20-25 ° C for 1 hour to precipitate a large amount of solid. The solid was filtered, and the filter cake was washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake was vacuum dried to obtain the compound represented by formula I, rituximab tosylate, with an amount of 3.73 g, a yield of 80.2%, and an HPLC purity of 99.4%.
[0070] Example 11 Synthesis of the compound represented by formula I
[0071] At room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) was dissolved in 30 mL of tetrahydrofuran, and p-toluenesulfonic acid (1.93 g, 11.20 mmol) was slowly added dropwise, and the mixture was stirred at 20-25 ° C for 1 hour. A large amount of solid was precipitated, and the solid was filtered. The filter cake was washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake was vacuum dried to obtain the compound represented by formula I, i.e., rituximab tosylate, with an amount of 3.67 g, a yield of 81.0%, and a HPLC purity of 99.9%.
[0072] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0073] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A process for preparing rituximab tosylate, characterized in that: include: (1) contacting the compound represented by Formula 1 with the compound represented by Formula 2, glacial acetic acid, and NaBH(OAc)3 to obtain the compound represented by Formula 3; (2) contacting the compound represented by Formula 3 with L-DBTA to obtain the compound represented by Formula 4; (3) contacting the compound represented by formula 4 with p-toluenesulfonic acid to obtain the compound represented by formula I, rituximab tosylate, 2. The method according to claim 1, characterized in that In step (1), the following steps are included: maintaining the temperature at 5°C to 12°C, adding the compound represented by formula 1, the compound represented by formula 2, and glacial acetic acid to 1,2-dichloroethane, maintaining the temperature at 8°C to 10°C and stirring for 10 hours, then adding sodium triacetoxyborohydride (NaBH(OAc)3) to the reaction solution and heating it to 32°C to 40°C for reaction for 4 hours, then cooling the reaction solution to room temperature, adding saturated ammonium chloride solution to quench, then adding 1M NaOH aqueous solution to wash, adding ethyl acetate to extract twice, combining the organic phases, adding saturated brine to wash, drying over anhydrous sodium sulfate, and concentrating the organic phase under reduced pressure. The concentrate is purified by silica gel column chromatography using a petroleum ether / ethyl acetate mixed solvent to obtain the compound represented by formula 3.
3. The method according to claim 2, characterized in that In step (1), the molar ratio of the compound represented by formula 1 to the compound represented by formula 2, glacial acetic acid, and NaBH(OAc)3 is 1:(1.0-1.15):1.0:(1.3-1.6), and preferably the molar ratio of the compound represented by formula 1 to the compound represented by formula 2, glacial acetic acid, and NaBH(OAc)3 is 1:1.05:1.0:1.
4.
4. The method according to claim 2, characterized in that: In step (1), the temperature is preferably raised to 36°C for a reaction time of 4 hours; Optionally, in step (1), the volume ratio of the petroleum ether / ethyl acetate mixed solvent is 1:(6-10), preferably the volume ratio of the petroleum ether / ethyl acetate mixed solvent is 1:
8.
5. The method according to claim 1, characterized in that In step (2), the following steps are included: adding methanol to a reaction bottle containing the compound shown in Formula 3 and (-)-dibenzoyl-L-tartaric acid (L-DBTA) at room temperature, stirring and dissolving, heating to reflux, stirring and reacting for 10 to 12 hours, observing that a large amount of solid is precipitated in the solution, cooling the reaction solution to room temperature, stirring for 2 hours and then filtering, adding methanol to the filter cake for elution, adding dichloromethane and 5% Na2CO3 solution, stirring and dissolving, separating the liquids, adding saturated brine to the organic phase for washing, drying over anhydrous sodium sulfate, and concentrating under reduced pressure to obtain a solid, which is the compound shown in Formula 4.
6. The method according to claim 4, characterized in that In step (2), the molar ratio of the compound represented by formula 3 to L-DBTA is 1:(0.6-0.7), preferably the molar ratio of the compound represented by formula 3 to L-DBTA is 1:0.65; Optionally, in step (2), the reaction time of heating to reflux state and stirring is preferably 11 hours.
7. The method according to claim 1, characterized in that In step (3), the following steps are included: at room temperature, dissolving the compound represented by formula 4 in an organic solvent C, slowly adding p-toluenesulfonic acid, maintaining stirring at room temperature for 1 hour, precipitating a large amount of solid, filtering the solid, washing the filter cake with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallizing with methanol. The filtered filter cake is vacuum dried to obtain the compound represented by formula I, rituximab tosylate.
8. The method according to claim 7, characterized in that In step (3), the molar ratio of the compound represented by formula 4 to p-toluenesulfonic acid is 1:(1.05-1.2), preferably the molar ratio of the compound represented by formula 4 to p-toluenesulfonic acid is 1:1.
1.
9. The method according to claim 7, characterized in that: In step (3), the organic solvent C is at least one selected from ethanol, acetone, or tetrahydrofuran.
10. The method according to claim 1, characterized in that In step (1), the following steps are included: maintaining the temperature at 5°C to 12°C, adding the compound represented by formula 1 (16.72 g, 0.10 mol), the compound represented by formula 2 (14.08 g, 0.105 mol), and glacial acetic acid (6.0 g, 0.10 mol) to 1,2-dichloroethane (200 mL), maintaining the temperature at 8°C to 10°C and stirring for 10 hours, then adding NaBH(OAc)3 (29.67 g, 0.14 mol) to the reaction solution and heating to 36°C for reaction; 4 hours, then the reaction solution was cooled to room temperature, saturated ammonium chloride solution (20 mL) was added to quench, then 1M NaOH aqueous solution (150 ml) was added to wash, ethyl acetate was added to extract twice (150 ml each time), the organic phases were combined, 150 ml of saturated brine was added to wash, and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure, and the concentrate was purified by silica gel column chromatography with a mixed solvent of petroleum ether / ethyl acetate in a volume ratio of 1:8 to obtain the compound shown in formula 3, with an amount of 21.80 g and a yield of 76.4%; In step (2), the following steps are included: at room temperature, adding 200 mL of methanol to a reaction bottle containing the compound of formula 3 (18.90 g, 66.24 mmol) and (-)-dibenzoyl-L-tartaric acid (L-DBTA) (15.43 g, 43.06 mmol), stirring and dissolving, heating to reflux, stirring and reacting for 11 hours, observing that a large amount of solid precipitates in the solution, cooling the reaction solution to room temperature, crystallizing and stirring for 2 hours, and then filtering, adding 20 mL of methanol to the filter cake for elution, adding 150 mL of dichloromethane and 150 mL of 5% Na2CO3 solution, stirring and dissolving, separating the liquids, adding 150 mL of saturated brine to the organic phase for washing, drying over anhydrous sodium sulfate, and concentrating under reduced pressure to obtain a solid, namely the compound of formula 4, with an amount of 8.30 g, a purity of 98.4%, ee>98.5%, and a yield of 43.9%; In step (3), the following steps are included: at room temperature, the compound represented by formula 4 (2.9 g, 10.16 mmol) is dissolved in 30 mL of ethanol, p-toluenesulfonic acid (1.93 g, 11.20 mmol) is slowly added dropwise, and the mixture is stirred at room temperature for 1 hour to precipitate a large amount of solid, the solid is filtered, the filter cake is washed with an appropriate amount of ethylene glycol dimethyl ether, and then recrystallized with 10 ml of methanol. The filtered filter cake is vacuum dried to obtain the compound represented by formula I, ibutinib tosylate, with an amount of 3.96 g, a yield of 85.2%, and an HPLC purity of 99.8%.
Citation Information
Patent Citations
Preparation method of PF-06651600 intermediate
CN112430235A
Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
CN112888691A
Preparation method of key intermediate of JAK3 enzyme inhibitor
CN113121413A
Synthesis method of Ritlecitinib key intermediate
CN120329305A
